DOP2011000011A - Formulacion farmaceutica de eprosartan - Google Patents
Formulacion farmaceutica de eprosartanInfo
- Publication number
- DOP2011000011A DOP2011000011A DO2011000011A DO2011000011A DOP2011000011A DO P2011000011 A DOP2011000011 A DO P2011000011A DO 2011000011 A DO2011000011 A DO 2011000011A DO 2011000011 A DO2011000011 A DO 2011000011A DO P2011000011 A DOP2011000011 A DO P2011000011A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- eprosartan
- dose
- administered
- compound
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención descripta se refiere a un método de tratamiento de un trastorno modulado mediante el bloqueo de los receptores de angiotensina 11 (AII), y particularmente seleccionados del grupo que consiste de hipertensión, falla cardíaca congestiva, falla renal, y combinaciones de los mismos, administrando a un sujeto en necesidad del mismo una dosis efectiva de un compuesto de eprosartan. Con referencia a la Dosis Diaria Efectiva Recomendada de 600 mg, calculada en base a eprosartan administrada en forma de mesilato de eprosartan, ahora se ha hallado que puede ser administrada una dosis menor de eprosartan cuando el compuesto de eprosartan es eprosartan ácido. Esta dosis está en el rango de desde 410 a 490 mg, lo más preferiblemente aproximadamente 450 mg.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08160211 | 2008-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2011000011A true DOP2011000011A (es) | 2011-01-31 |
Family
ID=39731507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2011000011A DOP2011000011A (es) | 2008-07-11 | 2011-01-07 | Formulacion farmaceutica de eprosartan |
Country Status (21)
Country | Link |
---|---|
US (2) | US20100010062A1 (es) |
EP (1) | EP2317987B1 (es) |
JP (1) | JP2011527314A (es) |
KR (1) | KR20110031226A (es) |
CN (1) | CN102088961A (es) |
AR (1) | AR072477A1 (es) |
AU (1) | AU2009268044A1 (es) |
BR (1) | BRPI0915455A2 (es) |
CA (1) | CA2730008A1 (es) |
CO (1) | CO6331424A2 (es) |
DO (1) | DOP2011000011A (es) |
EA (1) | EA201170182A1 (es) |
EC (1) | ECSP10010701A (es) |
IL (1) | IL210001A0 (es) |
MX (1) | MX2011000349A (es) |
NZ (1) | NZ589904A (es) |
PE (1) | PE20110412A1 (es) |
TW (1) | TW201006826A (es) |
UA (1) | UA100434C2 (es) |
WO (1) | WO2010003996A1 (es) |
ZA (1) | ZA201100223B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5910311B2 (ja) * | 2012-05-23 | 2016-04-27 | ニプロ株式会社 | 医薬錠剤およびその製造方法 |
CN102755322B (zh) * | 2012-07-24 | 2013-12-11 | 兆科药业(广州)有限公司 | 一种乐卡地平和阿托伐他汀复方制剂 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0955294B1 (en) * | 1989-06-14 | 2003-09-24 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acid |
US5656650A (en) * | 1990-12-14 | 1997-08-12 | Smithkline Beecham Corp. | Angiotensin II receptor blocking compositions |
IL136142A0 (en) * | 1997-11-17 | 2001-05-20 | Smithkline Beecham Corp | High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
JP4575594B2 (ja) * | 1998-07-20 | 2010-11-04 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 経口用固体剤形のエプロサルタン配合の生体内強化性処方 |
CA2547657A1 (en) * | 2003-12-01 | 2005-06-16 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising lercanidipine |
EP1734953A4 (en) * | 2004-03-02 | 2008-08-20 | Abeille Pharmaceuticals Inc | CO-PR PARATIONS OF KITS OF BIOACTIVE AGENTS |
FR2882260A1 (fr) * | 2005-02-21 | 2006-08-25 | Flamel Technologies Sa | Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii |
FR2886150B1 (fr) * | 2005-05-24 | 2007-08-24 | Flamel Technologies Sa | Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique |
US20070116762A1 (en) * | 2005-11-07 | 2007-05-24 | Wilson Edward S | Compositions of stabilized ramipril in combination with another active agent |
-
2009
- 2009-07-07 AR ARP090102539A patent/AR072477A1/es not_active Application Discontinuation
- 2009-07-08 TW TW098123060A patent/TW201006826A/zh unknown
- 2009-07-09 JP JP2011517158A patent/JP2011527314A/ja active Pending
- 2009-07-09 US US12/500,425 patent/US20100010062A1/en not_active Abandoned
- 2009-07-09 KR KR1020117003089A patent/KR20110031226A/ko not_active Application Discontinuation
- 2009-07-09 EP EP09780358.9A patent/EP2317987B1/en active Active
- 2009-07-09 EA EA201170182A patent/EA201170182A1/ru unknown
- 2009-07-09 CN CN200980127192XA patent/CN102088961A/zh active Pending
- 2009-07-09 CA CA2730008A patent/CA2730008A1/en not_active Abandoned
- 2009-07-09 PE PE2011000022A patent/PE20110412A1/es not_active Application Discontinuation
- 2009-07-09 UA UAA201101523A patent/UA100434C2/ru unknown
- 2009-07-09 WO PCT/EP2009/058724 patent/WO2010003996A1/en active Application Filing
- 2009-07-09 NZ NZ589904A patent/NZ589904A/xx not_active IP Right Cessation
- 2009-07-09 MX MX2011000349A patent/MX2011000349A/es active IP Right Grant
- 2009-07-09 BR BRPI0915455A patent/BRPI0915455A2/pt not_active IP Right Cessation
- 2009-07-09 AU AU2009268044A patent/AU2009268044A1/en not_active Abandoned
-
2010
- 2010-12-15 IL IL210001A patent/IL210001A0/en unknown
- 2010-12-21 EC EC2010010701A patent/ECSP10010701A/es unknown
-
2011
- 2011-01-07 DO DO2011000011A patent/DOP2011000011A/es unknown
- 2011-01-07 ZA ZA2011/00223A patent/ZA201100223B/en unknown
- 2011-01-14 CO CO11003597A patent/CO6331424A2/es not_active Application Discontinuation
-
2012
- 2012-08-03 US US13/565,872 patent/US20120302555A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2010003996A1 (en) | 2010-01-14 |
CN102088961A (zh) | 2011-06-08 |
AU2009268044A1 (en) | 2010-01-14 |
MX2011000349A (es) | 2011-02-22 |
EA201170182A1 (ru) | 2011-08-30 |
EP2317987A1 (en) | 2011-05-11 |
US20120302555A1 (en) | 2012-11-29 |
UA100434C2 (en) | 2012-12-25 |
JP2011527314A (ja) | 2011-10-27 |
PE20110412A1 (es) | 2011-07-04 |
KR20110031226A (ko) | 2011-03-24 |
CO6331424A2 (es) | 2011-10-20 |
TW201006826A (en) | 2010-02-16 |
US20100010062A1 (en) | 2010-01-14 |
ECSP10010701A (es) | 2011-01-31 |
BRPI0915455A2 (pt) | 2017-06-27 |
NZ589904A (en) | 2012-08-31 |
ZA201100223B (en) | 2011-10-26 |
IL210001A0 (en) | 2011-02-28 |
AR072477A1 (es) | 2010-09-01 |
CA2730008A1 (en) | 2010-01-14 |
EP2317987B1 (en) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY37998A (es) | Agentes antivirales contra la hepatitis b | |
CL2021001288A1 (es) | Heterociclos funcionalizados como agentes antivirales | |
EA201690033A3 (ru) | Морфинановые соединения | |
EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
CU23814A3 (es) | Emulsión intravenosa de butilftalida y aplicación de la misma | |
CL2012002356A1 (es) | Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras. | |
ECSP055935A (es) | Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension | |
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
CO6761298A2 (es) | Combinaciones que comprenden antipsicóticos atípocos y antagonistas taar1 | |
UY32731A (es) | Nuevos derivados de piperidin-ilidenaminooxi-piperidin, composiciones farmacéuticas y métodos relacionados con ellos | |
SV2011003907A (es) | Composiciones antimicrobianas | |
UY38383A (es) | Heterociclos funcionalizados como agentes antivirales | |
PH12014502331B1 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
CO6321158A2 (es) | Formulacion oral | |
MA31706B1 (fr) | Formulations galéniques de composés organiques | |
MX2009012472A (es) | Combinacion que comprende acido pirrolidona-5-carboxilico y por lo menos un compuesto de citrulina, arginina y asparragina, y su uso en el tratamiento de dermatitis atopica. | |
PH12019500328A1 (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
ECSP15033787A (es) | Nueva formulación granular de disolución rápida que tiene solubilidad mejorada | |
PA8784901A1 (es) | Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial | |
EA201390979A1 (ru) | Композиции бензимидазолов с модифицированным высвобождением | |
EA200970127A1 (ru) | Модулятор рецепторов глюкокортикостероидов и способы его применения | |
DOP2011000011A (es) | Formulacion farmaceutica de eprosartan | |
ATE529127T1 (de) | Pharmazeutische zusammensetzung mit arazym zur prävention von leberfunktionsstörung | |
CU20110232A7 (es) | Inyección de diacetato de ipamorelin y soluciones de la infusión | |
CR20110024A (es) | Formulación farmáceutica de eprosartan |